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Abstract 
Introduction: The Comprehensive in vitro Proarrhythmia Assay (CiPA) is a nonclinical Safety 
Pharmacology paradigm for discovering electrophysiological mechanisms that are likely to confer 
proarrhythmic liability to drug candidates intended for human use. 
Topics covered: Key talks delivered at the ‘CiPA on my mind’ session, held during the 2015 Annual 
Meeting of the Safety Pharmacology Society (SPS), are summarized. Issues and potential solutions 
relating to crucial constituents [e.g., biological materials (ion channels and pluripotent stem cell-
derived cardiomyocytes), study platforms, drug solutions, data analysis, etc.] of CiPA core assays are 
critically examined.  
Discussion: In order to advance the CiPA paradigm from the current testing and validation stages to a 
research and regulatory drug development strategy, systematic guidance by CiPA stakeholders is 
necessary to expedite solutions to pending and newly arising issues. Once a study protocol is proved to 
yield robust and reproducible results within and across laboratories, it can be implemented as qualified 
regulatory procedure. 
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Abbreviations: AP, action potential; ADP90, action potential duration at 90% repolarization; CaV, 
voltage dependent calcium channel; CDI, Cellular Dynamics International; CiPA, comprehensive in 
vitro proarrhythmia assay; CROs, contract research organizations; CSA, consortium for safety 
assessment; DMSO: dimethyl sulfoxide; FP, field potential; FPD, field potential duration; FPDcB, 
FPD corrected according to the Bazett formula; FPDcF, FPD corrected according to the Fridericia 
formula; GEVI: genetically-encoded voltage indicators; GLP: good laboratory practices; HESI, Health 
and Environmental Sciences Institute; HPF, high pass filter; hiPSC-CMs, human induced pluripotent 
stem cell cardiomyocytes; HTS, high throughput screening; ICH, International Conference on 
Harmonization; ICaL, L-type (long-lasting voltage-gated) depolarizing calcium current; IKr, rapidly 
activating delayed rectifier potassium current; IhERG, human ether-a-go-go-related gene potassium 
current; IKs, slowly activating delayed rectifier potassium current; IK1, inward rectifier potassium 
current; Ito, transient outward potassium current; INaFast, fast depolarizing sodium current; INaLate, late 
depolarizing sodium current; ICWG, ion channel working group; ILSI, International Life Sciences 
Institute; hiPSC-CMs,: human induced pluripotent stem cell derived cardiomyocytes; ISI, interspike 
interval; ISWG, in silico working group; LQTS, long QT syndrome; JiCSA, Japan iPS Cardiac Safety 
Assessment consortium; JSPS, Japan Safety Pharmacology Society; LQT, long QT interval syndrome; 
LPF, low pass filter; MEA, multi-electrode arrays; MWG, myocyte working group; NaV, voltage 
dependent sodium channel QMS, Quality Management System; QTc, QT interval corrected according 
to the Fridericia algorithm; SD: Standard deviation; SEM: standard error of the mean; SPS, Safety 
Pharmacology Society; TdP, Torsade de Pointes arrhythmia; TQT, thorough QT study, Vmax, maximal 
velocity of depolarization; VSD, Voltage-sensitive dyes; VSO, Voltage-sensitive optical devices; WG, 
working group.  
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1. Introduction 
CiPA is a novel Safety Pharmacology paradigm undergoing systematic evaluation for fitness to 
discover candidate drugs with the potential to trigger ventricular arrhythmic events in humans. If these 
evaluation efforts succeed, CiPA will become a Safety Pharmacology screening tool for drug research 
and development purposes (Cavero & Holzgrefe, 2015). 
The CiPA paradigm has been designed to provide an accurate and comprehensive assessment of the 
cardiac ventricular electrophysiological properties of candidate drugs for identifying mechanisms that 
may mediate life-threatening ventricular proarrhythmic events. This preclinical approach can be 
considered as an extension of the currently applied ICH S7B guideline strategy (ICH, 2005a) which is 
designed to detect whether a candidate drug adversely affects the physiological function of the cardiac 
channel encoded by the ether-à-go-go related gene (hERG) which conducts the delayed rectifier K+ 
current (IKr). This concern arises primarily from clinical findings that drug-induced hERG inhibition 
can provoke a particular type of polymorphic ventricular arrhythmia called torsade de pointes (TdP). 
This tachyarrhythmia, at times, culminates in irreversible ventricular fibrillation. However, within the 
large number of drugs demonstrating potent IKr channel blocking activity in the in vitro patch clamp 
assay, some are free of proarrhythmic effects in integrated nonclinical assays, as well as in man 
(Kannankeril, Roden, & Darbar, 2010; Vandenberg, Perry, Perrin, Mann, Ke, & Hill, 2012). 
CiPA is an initiative sponsored by a multi-partner international consortium which includes the 
FDA, HESI, CSRC, SPS, Japan National Institute of Health Sciences, Health Canada, European 
Medicines Agency, Pharmaceutical and Japan Medical Devices Agency, Japan iPS Cardiac Safety 
Assessment Group, academic electrophysiologists, in silico modelers, pharmaceutical industry 
associations, contract research organizations (CROs), stem cell manufacturers, and companies 
producing hardware and software for Safety Pharmacology research. 
The CiPA core components are: 
1) In vitro patch clamp assays in stably expressed recombinant human ion channels. The aim of 
these studies is to evaluate the effects of candidate drugs on key depolarizing and repolarizing ion 
currents participating in the formation of human ventricular action potential (AP). 
2) An in silico AP assay which is performed to verify whether the results obtained in the previous 
investigations engender either phenotypic indicators signaling proarrhythmic liability on the 
human ventricular AP [e.g., prolongation of AP duration (e.g;, ADP90), EADs (Gintant, 2008)] 
evidenced on the AP profile generated by a mathematical model of the human ventricular 
myocyte AP (O'Hara, Virag, Varro, & Rudy, 2011) or mechanism-related proarrhythmic metrics 
(section 2.3) allowing the latter model to classify each drug candidate as no/low, intermediate or 
high  proarrhythmic risk agents. 
3) An in vitro assay designed to investigate the electrophysiological effects of candidate drugs in 
ventricular cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). 
The aim is to confirm or cast doubt on the in silico predictions and to broaden the cardiac safety 
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assessment of the candidate drug to include additional proarrhythmic mechanisms not 
discoverable by the ion channel assay investigation or in silico analysis. 
The CiPA initiative encompasses also the E14 guideline (ICH, 2005b) since it has the potential to 
de-emphasize the clinical thorough QT/QTc study (TQT) and replace it with an intensive Phase ECG 
investigation (Cavero, Holzgrefe, & Clements, 2016). 
The first part of this article provides extended summaries of key presentations on the CiPA 
paradigm given at the ‘CiPA on my mind session’ which was part of the scientific program of the 15th 
Annual Meeting of the Safety Pharmacology Society (SPS) held in Prague in October 2015. 
The second part of this report threads through issues concerning biological material, experimental 
platforms, measured parameters, and data analysis approaches that need to be resolved to qualify each 
CiPA core assay for Safety Pharmacology research and regulatory purposes. While available solutions 
for these issues are mentioned in this report, it will be the role of the CiPA Steering Committee and the 
various CiPA Working Groups and Teams to recommend the best possible solutions for bench 
stakeholders. 
2. Key presentations from ‘CiPA on your mind’ session held at the Annual Meeting of 
the Safety Pharmacological Society 
2.1. CiPA introduction. Ongoing activities (CiPA Steering Team) and updates. Dr. G. Gintant, 
Abbvie,North Chicago, IL, USA 
The 2015 CiPA hiPSC-CM pilot study program was designed to test whether a set of reference drugs 
yielded reproducible effects on field potentials (FP) measured with multi-electrode arrays (MEA) and 
action potentials (AP) obtained by using voltage-sensitive optical dye (VSD) (Cavero & Holzgrefe, 
2014). The knowledge acquired from these investigations will provide indications for optimizing 
experimental protocols with regard to the selection of the most informative parameters to measure, 
sampling times during the execution of a protocol, analytical approaches, and data reporting formats. 
In September 2015, the FDA Cardiac Safety Committee (CSC), through an FDA Broad Agency 
Announcement (BAA) awarded a grant to HESI for ‘Validating human stem cell cardiomyocyte 
technology for better predictive assessment of drug-induced cardiac toxicity’ (HESI, 2014). This 
endowment will be used to finance studies to characterize the electrophysiological properties of 
hiPSC-CMs in studies using MEA and VSD platforms. 
HESI funding will also support a pilot Phase I study (to be completed by the end of 2016) of 12 
reference drugs selected by the CiPA Clinical Subteam) which includes compounds with no/low 
(diltiazem, mexiletine, ranolazine and verapamil), intermediate (chlorpromazine, cisapride, 
terfenadine, and ondansetron), and high proarrhythmic risk (quinidine, bepridil, dofetilide, and 
sotalol). These drugs were selected from a larger set of 28 drugs [Table 1 in (Gintant, Sager, & 
Stockbridge, 2016)] which  the CiPA Clinical Translation Working Group proposed for achieving the 
validation of the components of the CiPA paradigm (Cavero & Holzgrefe, 2015). The drugs within 
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this set have different physico-chemical properties and cover a wide spectrum of electrophysiological 
endpoints (in particular, the degree of torsadogenic risk, multichannel blockade, and variable degrees 
of hERG channel blockade). 
The results obtained from ongoing studies will be used to test whether the CiPA in vitro ion channel 
assays provide appropriate markers of risk (metrics) for training the in silico AP model to recognize 
and assign an appropriate level of proarrhythmic risk to each of the 12 initial reference drugs. Phase II 
studies will investigate the entire collection of 28 drugs. 
The CiPA Steering Committee has accepted a proposal from the Japan iPS Cardiac Safety 
Assessment (JiCSA) group to sponsor and coordinate, within Japan, an experimental study of 60 
compounds with varying degrees of proarrhythmic potential for testing and evaluating the CiPA 
hiPSC-CM assays. 
The CiPA Steering Committee and the ICH S7B and E14 Working Groups have initiated discussions 
to define the possible place of the CiPA paradigm within the upcoming revisions of these regulatory 
documents. For instance, the E14 Q&As (R3), released by the ICH in December 2015 (ICH, 2015) 
opens the avenue to perform intensive ECG studies, in replacement of the thorough QT/QTc study, 
conducted within Phase I safety clinical investigations. The latter trials, if are designed in accordance 
with the rich cardiac electrophysiological knowledge generated by the CiPA assays, can be expected 
to accelerate and improve the human assessment of the proarrhythmic safety profile of candidate drugs 
(Cavero, et al., 2016). 
2.2. Ion channel project update. Dr. Bernard Fermini Global Safety Pharmacology, Pfizer, Groton, 
CT, USA and Dr. Najah Abi Gerges, AnaBios Corporation, San Diego, CA, USA, 
The Ion Channel Working Group (ICWG), under the auspices of the Safety Pharmacology Society, 
was charged with the following tasks: 
1) Selection of cardiac ventricular ion channels requiring experimental scrutiny because drug-
induced perturbations of their physiological function have been found to mediate proarrhythmic 
events in patients (Kannankeril, et al., 2010; Vandenberg, et al., 2012); 
2) Establishing best practice protocols for manual and automated patch-clamp studies to determine 
whether candidate drugs disrupt human ventricular ion channel functions; 
3) Performing pilot studies to identify those ion channel parameters that can best predict a 
proarrhythmic liability of candidate drugs (Fermini, Hancox, Abi-Gerges, Bridgland-Taylor, 
Chaudhary, Colatsky, et al., 2016). 
For the first core assay of the CiPA paradigm, the ICWG selected three depolarizing [INaFast (NaV1.5 
peak current), INaLate (NaV1.5 late current), ICa (Cav1.2),] and three repolarizing [(Ito (KV4.3), IKr 
(hERG), and IKs (KVLQT1/KCNE1)] cardiac ion channels and IK1 (Kir2.1) channel which can behave 
as a depolarizing or repolarizing current according to the phase of the cardiac cycle to which it 
contributes. This selection was made by taking into consideration the key role played by the channel in 
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shaping the ventricular depolarization and repolarization phases of the ventricular AP profile. A 
definitive triage will be made according to experimental data collected by ICWG and the in silico 
working groups (ISWG) and by taking into consideration of the results of an SPS inquiry concerning 
these channels most often investigated by the pharmaceutical industry for assessing the cardiac safety 
of candidate drugs which are INaFast, ICaL, IKr, and IKs. 
For each of the seven ion channels selected by the ICWG, two sets of experimental protocols have 
been prepared: 
1) Physiological protocols. These are designed to mimic the behaviors of an ion channel during the 
cardiac action potential by employing AP-like current stimuli to activate channels for generating 
IC50 values as well as data on voltage-, rate- and use-dependence, and channel activation, 
inactivation, and deactivation rates. The physiological protocol for IKr has been tested in manual 
patch clamp platforms and the results of the study have been recently published (Crumb, 
Vicente, Johannesen, & Strauss, 2016). The data obtained from the latter (pilot) and the ongoing 
post-pilot (investigating the 12 reference drugs listed in section 2.1) studies will be used by the 
in silico working Group (ISWG) to train the O’Hara-Rudy model (O'Hara, et al., 2011) to assign 
the correct proarrhythmic liability (no/low, intermediate, and high). 
2) Dynamic block protocols (Milnes, Witchel, Leaney, Leishman, & Hancox, 2010) are designed to 
generate parameters (e.g., drug channel affinity (IC50), kinetics, and state-dependence  of the 
drug-channel interaction) of potential interest for the in silico assay. Pilot IKr studies on 
dofetilide, cisapride, and verapamil, applying this protocol have already been carried out at room 
and physiological (37°C) temperatures by using manual patch clamp setups. Additional, ongoing 
patch clamp pilot studies on the effects of other reference hERG blocking drugs according to a 
dynamic protocol are expected to be completed within 2Q 2016. It is of interest to note that 
results reported by (Milnes, et al., 2010) indicate a marked ability of cisapride, but not 
dofetilide, to interact with the hERG channel on a dynamic pulse-by-pulse basis. These authors 
note that that if a candidate drug were to undergo voltage-dependent cycles of dissociation and 
reassociation, its effects might be overestimated by hERG-blocking assays using certain 
stimulus frequencies and voltage protocols. For these drugs (e.g., cisapride, droperidol, 
haloperidol, amiodarone) the time period between resting and gated (open/inactivated) states 
should be well-controlled during concentration-response studies and this may be achieved by 
using continuous voltage clamp applying a sustained-depolarization [Fig. 6 in (Milnes, et al., 
2010)]. 
The ability of cisapride to rapidly associate and dissociate from the hERG channel during the AP 
cycle may account for the large variability of its potency as blocker of the hERG channel 
reported in the literature [Table 2 in (Milnes, et al., 2010)]. In contrast, dofetilide is a slow 
hERG blocker which becomes and remains associated to the hERG channel throughout the AP 
cycle. Hence, patch clamp studies applying dynamic block protocols may provide useful 
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information on the development of channel blockade produced by a drug candidate and may 
account for possible variation in a drug IC50 determined by using different channel activation 
voltage protocols, and possibly, at different study temperatures. 
The protocols tested in pilot and post-pilot studies are consensus protocols. However, the protocols, 
that will be officially proposed by the ICWG for the CiPA ion channel assays, will be best practice in 
nature since they will incorporate the knowledge acquired during the testing and validation studies. 
All manual patch protocols, starting from those on hERG channels, will be adapted for high 
throughput screening (HTS) platform application and optimized to yield data of the same high quality 
as those obtained or obtainable with the manual patch clamp technique. 
2.3. In silico modeling: update and next steps. Dr. Sara Dutta, Division of Applied Regulatory Science 
OCP/OTS/CDER/FDA, Silver Spring, MD, USA 
The CiPA ISWG has been entrusted with selecting, training, and making publicly available a human 
(adult) ventricular AP computational model that has the power to detect the proarrhythmic potential of 
candidate drugs from patch clamp results generated in the CiPA cardiac ion channel assays. 
The O’Hara-Rudy model (O'Hara, et al., 2011) was selected as a starting point for in silico 
simulations by a large panel of leading cardiac modeling experts because it is the cardiac cell 
electrophysiological model most tightly linked to human ventricular cell data obtained from over 100 
undiseased human hearts. This choice is further supported by the following desirable features 
characterizing the model: 
1) Simplicity of use; 
2) Transparency of assumptions; 
3)  Direct relationship to experimentally derived and verifiable datasets; 
4) Freedom from intellectual property protection; 
5) Implementation as a community resource that will not require specialized hardware or software to 
be used. 
The chief challenge for in silico programming scientists is to provide a model that can predict the 
clinical proarrhythmic risk of candidate drugs from in vitro ion channel results generated in patch 
clamp studies. In order to attain this goal, the ICWG should find reasonable solutions to the following 
issues: 
1) Identification of key ion channels and parameters for accurate in silico prediction of the 
proarrhythmic risk of a drug candidate; 
2) Selection of the most appropriate experimental protocol for generating, in the envisaged assay 
system (manual or automatic patch clamp), the most robust ion channel results for in silico 
purposes; 
3) Definition of quality control criteria for data input into the computational model (Elkins, Davies, 
Brough, Gavaghan, Cui, Abi-Gerges, et al., 2013). 
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Issues relating to the use of the O’Hara-Rudy model (O'Hara, et al., 2011), which may still require 
attention, include: 
1) Optimization of the basic model performance; 
2) Identification of the best method to represent drug-channel interactions; 
3) Enabling the ready use of patch clamp data as a model input; 
4) Definition of the underlying principles to evaluate the fitness-for-purpose of simulation protocols. 
Of particular importance, the in silico assay-generated information on the clinical proarrhythmic risk 
of a candidate drug should: 
1)  Be mechanism-based (e.g., either producing phenotypic manifestations on the reconstructed AP 
such as EADs, or linked to one or more functional parameters, such as the value of the net 
repolarization current or amount of current necessary to trigger EADs); 
2)  Enable the rank categorization of a candidate drug into no/low, intermediate, and high 
proarrhythmic risk in relation to reference drugs assigned to these three classes by the CiPA 
Clinical Translational Working Group (Cavero & Holzgrefe, 2015); 
3)  Be usable for regulatory requirements. 
In order to be compatible with the O’Hara-Rudy model (O'Hara, et al., 2011), patch clamp data 
should be obtained in ion channel preparations that generate data qualitatively and quantitatively 
similar to those measured in native adult cardiomyocytes since this model has been built according to 
electrophysiological data generated in preparations from human adult hearts. 
Possible issues concerning datasets obtained in patch clamp studies are: 
1) Certain cloned ion channels used for patch clamp studies may be expressed without their native 
complementary channel subunits that may play a critical role for physiological ion channel 
kinetics; 
2) High throughput screening (HTS) patch clamp platforms may use bath solutions that differ from 
the native environment within which human cardiac ion channels function; 
3) Currently available automated patch clamp platforms do not routinely provide the possibility of 
performing studies at physiological temperature, a feature necessary to observe rapid drug-
induced channel blockade. This may explain why the IC50 values of certain drugs differ 
substantially from those obtained at room temperature. For example, this is the case for 
erythromycin and d,l-sotalol which exhibited an IC50 against IKr of 1410 and 810 µM, 
respectively, at 24 °C and 199 and 278 µM at 37°C (Kirsch, Trepakova, Brimecombe, Sidach, 
Erickson, Kochan, et al., 2004). In order to overcome this potential issue, the ICWG is 
generating data with the 12 reference compound set (2.1) at 24 and 37°C in order to support an 
ISWG project aimed at developing a computational routine that can use 24°C data to predict the 
behavior of a drug at 37°C. However, most of IKr blockers studied to date appears to be 
characterized by IC50 values that are often virtually the same when determined at either 24° C or 
37° C  (Li, Dutta, Sheng, Tran, Wu, & Colatsky, 2016). However, it should be noted that for 
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certain drugs block kinetics (and, therefore, risk prediction) may be vastly different at room and 
physiologic temperatures.  
A candidate proarrhythmic metric under 
evaluation is the value of the residual net 
repolarizing current (Inet = IKr+ IKs + INaLate + 
ICaL which can be derived from the effects 
of a candidate drug on the repolarization 
phase under the ‘worse case’ EAD scenario 
which can be achieved by applying a 
current patch clamp step protocol. When 
Inet crosses 0 during repolarization, EADs 
are likely to occur [details in (Starmer, 
2005)]. 
Another proarrhythmic metric under 
evaluation obtainable from patch clamp 
studies is Ibias (µA/µF) current which is the 
threshold current necessary to trigger 
EADs in the absence and presence of a 
candidate drug. For instance, a drug 
concentration producing a 50% block of 
the hERG channel reduced the control 
value of Ibias (0.734) by 50% (0.375) (Gray 
& Huelsing, 2008). 
A new and potentially interesting 
proarrhythmic metric referred as a ‘TdPrisk’ (Fig 1) is firstly provided by calculating the area under the 
time-current profile (AUC) of three key ventricular AP currents (IKr, ICaL, and INaLate) determined by the 
application of an AP patch clamp protocol. Then, the ratios of the AUCs calculated during control 
condition and AUC under drug (at clinical concentrations) exposure were computed. Model inputs 
included experimental manual patch clamp IC50 data obtained at 37°C, amount of block for each 
channel produced by drug exposures achieved in patients, and current conductance scaled accordingly 
by the computational model (Crumb, et al., 2016). The TdPrisk metric is obtained in the following 
manner: TdPrisk= a(AUCICaL)Control/(AUCICaL)Drug + b(AUCINaLate)Control/(AUCINaLate)Drug + c 
c(AUCIKr)Control/(AUCIKr)Drug + d. The parameters a, b, c, and d are calculated using the proportional 
odds model (Brant, 1990). The input of the TdPrisk metric into the O’Hara-Rudy model provided a 
correct classification (Fig. 1) of the clinical proarrhythmic risk of the reference training set of 12 
drugs. 
 
Fig. 1. Proarrhythmic metric (TdPrisk) derived using three 
variables (see details in the text), namely, the AUC under 
IKr, ICaL and INaLate current contours generated in AP patch 
clamp studies under vehicle (control) and drug exposure (at 
human concentrations) conditions. Figure redrawn from a 
slide presented by Dr. Sara Dutta at the 2015 Annual 
Meeting of the Safety Pharmacological Society. The results 
of this figure should be considered exploratory in nature, 
since the data used to build it were not obtained using CiPA 
ion channel protocols and do not take into consideration 
hERG blocking kinetics. The authors of this work are in the 
process of further refining this metric and evaluating its 
performance using CiPA ion channel protocols and training 
compounds (personal communication) 
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The ability of the in silico assay to link accurately ion channel pharmacology to clinical risk 
prediction requires ion channel datasets characterized by minimal variability and high reproducibility 
within and across laboratories and platforms. 
The in silico CiPA shared community resource for public access will be accompanied by ISWG-
prepared documentation concerning: 
1) Quality of patch clamp data necessary to obtain reliable information from the AP model; 
2) Boundaries (in terms of compound actions) within which the model predictions can be considered 
reliable; 
3) Model assumptions; 
4) A description of how data should be input into the model to perform the computational analysis. 
Envisaged future development of the in silico model includes: 
1) Improvement of basic performance by refining the contribution of certain ionic currents, namely 
IK1 and INaLate; 
2) Use of drug-channel interaction data obtained from the dynamic block protocol for generating 
reliable proarrhythmic predictions for drugs specifically blocking IKr; 
3) Enabling the use of patch clamp data obtained at 24 °C to satisfy the model requirement for 37°C; 
4) Inclusion of disease state models by introducing the potential pathological influences of key 
cardiovascular changes due for example to bradycardia, hypokalemia, co-medications, and certain 
inherited LQT syndromes; 
5) Influence of data obtained by applying different patch protocols (current/voltage clamp) on 
simulation outputs; 
6) Additional considerations for use of in silico models as discussed in a recently published review 
article (Davies, Wang, Mirams, Caruso, Noble, Walz, et al., 2016). 
2.4. Current situation and future plan of Japan iPS Cardiac Safety Assessment (JiCSA) consortium. 
Yuko Sekino, National Institute of Health Sciences, Tokyo, Japan 
The JiCSA (Jicsa, 2016) is a joint consortium (funded by the Japan Ministry of Health, Labour and 
Welfare) under the leadership of the Japan National Institute of Sciences, the Japanese Pharmacology 
Society, pharmaceutical companies, CROs, academia, and research institute representatives.  
JiCSA established an active collaboration with the CiPA Steering Committee for participating in 
the testing and validation of core CiPA assays. 
The key objectives of the JiCSA are: 
1) Standardization and validation of Safety Pharmacology methods for identifying drugs which have 
the potential of inducing proarrhythmic events; 
2) Validation of the hiPSC-CM assay for regulatory purposes. 
In order to ensure the reproducibility of results of hiPSC-CMs electrophysiological investigations, 
the JiCSA is funding and conducting a study in four independent laboratories. The protocol of this 
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study calls for the use of the same hiPSC-CM line (CDI-iCells Cardiomyocytes) and the same 
experimental platform (MED64) for determining the effects of candidate drugs. In particular, to 
constrain sources of potential assay variability, technicians received special training concerning all 
experimental protocol provisions such as hiPSC-CM culture density, period to wait for the 
experimental procedure following cell seeding, drug sampling times for data points following drug 
exposure, temperature within the experimental well, and instrumentation calibration settings [e.g., high 
pass (HPF) and low pass (LPF) filters fixed at 0.1 Hz and 5 kHz, respectively]. A pilot study carried 
out according to these experimental conditions investigated five concentrations of reference hERG 
blockers added in a cumulative manner (observing 20 min intervals between 2 contiguous 
concentrations) to six independent experimental wells seeded with hiPSC-CMs. For statistical 
analysis, parameters derived from the field potential (FP) signals included interspike interval (ISI) in 
ms, field potential duration (FPD) in ms, early afterdepolarizations (EAD) incidence, and cell 
monolayer beating arrest. FPD values were corrected by using Fridericia [(FPDcF= FPD / (ISI / 
1000)1/3] or Bazett (FPDcB = FPD / (inter-spike interval / 1000)1/2]) formula  (Nakamura, et al., 2014; 
Asakura et al, 2015).Steady state FP signals (golden waves) within the exposure time selected for 
measuring ISI and FPD were characterized by an FPA ≥200 µV, an FPDcF ≥340 ms, and a second 
peak amplitude following the FP spike ≥ 15 µV. This study provided evidence that FPD was of greater 
amplitude at 0.1 Hz than with a 1.0 Hz high pass filter. The use of 1 Hz high pass filter (HPF) reduced 
FPD prolongation and obscured EAD detection produced by hERG blockers. The application of the 
above protocol by four geographically separated research sites to the study of E-4031 yielded the 
following results: a 3 nM concentration produced a 10% increase in FPDcF in all laboratories, 10 nM 
produced EADs in 2/6 preparations in 2 laboratories and in 5/6 preparations in the remaining 
laboratories. However, all four laboratories observed EADs in the 6 CM preparations after 10 min 
exposure at 30 nM. 
The JiCSA has asked its NIHS member to discuss with the Medical Devices Agency (PMDA) and 
the MHL, the regulatory acceptance of electrophysiology datasets produced by Japan Pharma in 
studies using hiPSC-CMs. At the level of the ICH organization and international regulatory 
institutions, JiCSA consortium envisages a gateway role for the acceptance of the CiPA assays for 
drug development and regulatory purposes. Finally, it plans to relay all data generated by the studies 
carried out under its sponsorship to the Pharmacological Evaluation Institute of Japan (PEIJ), an 
institution supported by a grant from the Japanese government for the development of widely 
applicable data validation platforms. 
2.5. Current situation and future plans in Japanese activity from the Kirishima meeting. Dr Atsushi 
Sugiyama, Department of Pharmacology, Faculty of Medicine, Toho University, Ota-ku, Tokyo, 
Japan 
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In January 2014, representatives of the Japanese health regulatory authority, pharmaceutical 
industry, and academia met in Kirishima (Japan) to discuss recent scientific advances and technologies 
for assessing the cardiac safety of candidate drugs (stem cell, computational, clinical, and integrated 
cardiac safety pharmacology-based methods). The meeting produced a consensus report (Sekino, 
2014) in which it is stressed, inter alia, the desire to involve Japanese scientists in the evaluation of the 
CiPA paradigm. Additionally, the meeting participants considered that the CiPA strategy should be 
enriched of an in vivo nonclinical assay as currently recommended by the ICH S7B guideline (ICH, 
2005b) and an early clinical ECG investigation to replace the ICH E14 (ICH, 2005b) TQT study 
(Cavero & Holzgrefe, 2014; Sugiyama, 2014) for ensuring the cardiac electrophysiological safety of 
candidate drugs for human use. At this meeting, the following dedicated working groups were 
designated: Stem Cell Pharmacology, In Silico Pharmacology, Clinical Pharmacology, and Integrated 
Cardiac Safety Pharmacology. The common mission of these groups is to contribute via appropriate 
initiatives to the determination of the human safety of candidate drugs selected for clinical 
investigation. 
The specific assignments of each group are briefly indicated here below. 
1) The Stem Cell Pharmacology Group has already established formal collaboration with the JiCSA 
for the development and standardization of experimental protocols to predict adverse drug 
reactions in nonclinical electrophysiological studies using hiPSC-CMs (see section 2.4). 
2) The In Silico Pharmacology Group in charge with thee activity on the development of a novel 
three dimension (3D), multi-scale, and multi-physics computational heart model (UT Heart) to 
correctly predict the proarrhythmic potential of candidate drugs from a 12-lead human ECG 
generated from nonclinical electrophysiological data obtained in automated patch clamp studies. 
In pilot studies, the UT Heart model satisfactorily predicted the expected human ECG effects of 
E-4031 and verapamil. 
3) The Clinical Pharmacology Group is tasked with the elaboration of Phase I ECG protocols that 
incorporate CiPA generated knowledge for the rapid, early clinical assessment of the 
proarrhythmic risk of candidate drugs in volunteers. 
4) The Integrated Safety Pharmacology Group is in charge of the integration of CiPA generated 
datasets into the nonclinical integrated risk assessment scheme recommended by the ICH S7B 
(ICH, 2005b). Additionally, it evaluates the predictability of candidate drug clinical 
proarrhythmic liability from the integrated analysis of nonclinical in vitro and in vivo data in 
conjunction with human ECG datasets obtained during Phase I investigations. 
3. The CiPA core assays: potential issues and possible solutions 
Safety Pharmacology studies should be designed, executed, and analyzed according to best scientific 
principles which entails, whenever possible, the adoption and scrupulous application of best practice 
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protocols in the execution of experimental procedures, particularly if these are carried out for 
regulatory purposes. 
The following sections examine issues requiring resolution to render CiPA core assays fit for the 
discovery of proarrhythmic mechanisms of candidate drugs. 
  Ion channel assays 3.1.
The objective of the CiPA ion channel assays is to determine whether candidate drugs disrupt the 
physiological function of any ion channels playing a fundamental role in the generation of a key 
electrical current contributing to the generation of the human ventricular AP. 
3.1.1 	Biological	material	for	the	CiPA	ion	channel	assay	
The core structural component of any cardiac ion channel is the pore-forming α-subunit protein 
which functions as pathway for the entry into, and the exit of ions (Na+, K+ and Ca2+) from, the CM. 
This protein is often complemented by one or more accessory proteins (subunit β, γ, δ) which 
modulate the pore activity. 
Ion channel functions can be easily explored in channel-proteins heterologously expressed in host 
cells. Whereas this expression process generally succeeds in the permanent expression of the ion 
conducting α-subunit protein, it does not routinely result in the co-expression of the multiple proteins 
needed to fully recapitulate the functions of the native channel. 
For the CiPA ion channel assay, the cloned cardiac ion channels should ideally possess the protein 
(primary, secondary, and tertiary) structure of native channels present on ventricular myocytes of 
healthy adult individuals, be stably expressed and functional within the host cells, and conduct a 
current density sufficiently large to allow its accurate measure in automated patch clamp platforms. 
3.1.2 Study	of	ICaL	in	heterologously	expressed	Ca2+	channels	
While various heterologous cell lines express IKr, IKs, and INaFast (Nav1.5) populations which conduct 
currents of elevated amplitude (≥ nA/cell), this is not generally the case for ICaL (Cav1.2) (Lory, 
Varadi, Slish, Varadi, & Schwartz, 1993; Nishimura, Takeshima, Hofmann, Flockerzi, & Imoto, 
1993). An additional experimental issue with heterologously expressed ICaL is that, with  dialysis of the 
intracellular constituents in the whole-cell recording setup, ICaL amplitude rapidly declines, making it 
difficult to accurately determine the time-course of the electrophysiological effects of candidate drugs 
(Bean, 1984). However, CaV1.2 screening conditions (peak current amplitude maximization and 
rundown attenuation) have recently been optimized for an automated planar patch clamp platform 
(PatchXpress® 7000A) in an HEK-293 cell line stably expressing a human L-type cardiac Ca2+ 
channel assembly of α1C, α2δ, and β2a proteins along with the Kir2.3 inward rectifier K+ channel. The 
concurrent expression of Kir2.3 is a crucial strategy, adopted for maintaining host cell resting potential 
below the threshold resting current activating CaV1.2. Indeed, this feature facilitates an effective 
culture of the HEK-293 cell line without the need of using Ca2+ channel blockers to prevent the 
excessive influx of extracellular Ca2+ that is detrimental to cell health and growth. The selected 
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automated patch platform routinely achieved GΩ seals and could record relatively small current 
amplitudes. Additionally, the assay conditions were optimized to yield IC50 values that were similar to 
those obtained in manual patch clamp studies for six established Ca2+ antagonists [diltiazem IC50: 44 
(automated patch champ) and 36 (manual patch clamp) µM, gallopamil: 17 and 1.1 µM, isradipine 2.2 
and 8 nM, nifedipine 22 and 16 nM, nimodipine 0.11 and 0.7 µM; verapamil 15 and 44 µM] and a 
Ca2+ agonist [S(-)-Bayk8644: 3.1 and 8.2 nM)] [Table 1 in (Balasubramanian, Imredy, Kim, 
Penniman, Lagrutta, & Salata, 2009)]. 
It should also be recalled that published potency (IC50) values for verapamil as a blocker of Cav1.2 
are rather heterogeneous. These differences are likely to depend not only from the voltage used to 
activate the channel and the presence or absence of subunits in the cloned Cav1.2, but also from the ion 
species (Ca2+ or Ba2+) used in the extracellular solution as charge carrier, and other experimental 
conditions such as study temperature (Dilmac, Hilliard, & Hockerman, 2004). 
Recently, a new CaV1.2 cell line by NMITT (Nmitt Pharmaservices, 2016) has been claimed to 
stably express all three subunits (α1c/β2/α2δ) present in the native CaV1.2 channel, have high success 
rates and reliable performance in automated patch clamp assays, afford rundown-free recordings, easy 
maintenance in cell culture, and possibility of custom adjustment of expression levels. 
These developments mandate that the cell line for the CiPA Ca2+ channel assay should be selected 
after appropriate pharmacological characterization in automated patch clamp platforms according to 
the ICWG protocols. 
3.1.3 Recording	the	small	INaLate		
INaLate is a small fraction of the classic “peak” INa current carried by NaV1.5 which is generated by 
voltage-dependent Na+ channels entering in burst-gating mode (repeated openings and closures) 
during myocyte depolarization. Genetic mutations causing defective INa channel inactivation, 
myocardial ischemia, and drug treatments can upregulate INaLate and expose patients to arrhythmic risk 
(Chevalier, Amuzescu, Gawali, Todt, Knott, Scheel, et al., 2014). Drugs like ranolazine, which is a 
blocker of this current, can reduce or prevent the proarrhythmic propensity inherent to hERG channel 
blockade (Gupta, Khera, Kolte, Aronow, & Iwai, 2015). In contrast, drugs enhancing INaLate can favor 
the development of arrhythmic events. This underscores the importance of the inclusion of INaLate in the 
CiPA ion channel panel.  
Because of the small amplitude of INaLate, agents which impair sodium channel inactivation such as 
veratridine or ATX-II, are routinely employed to overcome the small amplitude of this current in order 
to facilitate a more accurate characterization of candidate drug effects on this current. Nevertheless, it 
should be noted that it remains to be demonstrated that toxin-enhanced currents fully replicate native 
INaLate. 
A recent report describes the successful use of the CytoPatch™ automated patch-clamp platform and a 
HEK293 cell line stably expressing human NaV1.5 to determine INaLate (Chevalier, et al., 2014). The 
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baseline amplitude of this current averaged -10.4 ± 2.2 pA (n=18) during the last 100 ms of 300 ms 
depolarizing pulses to -10 mV from an initial holding potential of -100 mV, delivered at 0.33 Hz. 
Ranolazine (30 µM) reduced this current by 58.4 ± 3.5% (N=18) after a 3 min incubation. In contrast, 
in cells exposed for 5 min to 1 µM of veratridine INaLate was increased by 269.1 ± 16.1 % (n=28) from 
a baseline value of -12.4 ± 1.9 pA. 
3.1.4 Studying	IKs	in	automated	patch	clamp	platforms	
Under baseline conditions, the repolarizing current IKs contributes minimally to the repolarization 
phase of the cardiomyocyte AP which is primarily mediated by IKr. However, IKs exerts a major and 
vital function during sympathetic tone elevation leading to enhanced cardiac chronotropic and 
inotropic activity. Indeed, in these physiological settings, the increase in IKs limits the degree of QT 
interval prolongation that would result from the augmented CaV1.2 currents in the absence of the IKs 
intervention. Therefore, IKs functions as cardiac repolarization reserve antiarrhythmic mechanism 
precluding excessive, potentially dangerous repolarization lengthening (Jost, Papp, & Varro, 2007). 
Mutations in the gene encoding hKCNQ1 are responsible for the most common form of congenital 
long QT (LQT) syndrome (characterized by loss of channel function and referred to as LQT1 
syndrome) which predisposes affected patients to excessive QT interval prolongation during surges in 
adrenergic stimulation (e.g., occurring during intensive exercise and emotions) that can trigger lethal 
TdP events. Indeed, in these patients, IKs fails to increase as a counterbalance to the enhanced 
depolarization mediated by β-adrenergic stimulation to the heart (Jost, et al., 2007). 
HEK-293 cells transfected with the hKCNQ1 and hKCNE1 genes stably express IKs channels with 
voltage- and temperature-dependent gating characteristics, pharmacological responses, and β-
adrenergic modulation, as exhibited by IKs in native human CMs (Wu, Naiki, Ding, Ohno, Kato, Zang, 
et al., 2014). 
ICWG protocols should be tailored, tested, and validated for the ability to study IKs expressed in 
suitable cell models in automated patch clamp platforms that allow the adoption of desired pulsing 
rates. 
3.1.5 Points	to	consider	for	the	selection	of	automated	patch	clamp	equipment	and	studies	
Automated patch clamp platforms for CiPA ion channel assays should ideally: 
1) Provide easily obtained knowledge-rich proarrhythmic metrics for the in silico assay; 
2) Offer the possibility of studying candidate drugs at 37°C and at desired pacing rates; 
3) Allow sampling of well solutions for the determination of drug candidate concentrations; 
4) Allow superfusion of well preparations to uniformly expose CMs to desired concentrations; 
5) Offer the possibility of rapidly evaluating possible rundown phenomena; 
6) Ensure satisfactory reproducibility of results within and across platforms/cell lines/laboratories; 
7) Provide easily programmable features for standardizing dataset output. 
3.1.6 Validation	of	critical	components	of	automated	patch	clamp	platforms	
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Available automated patch clamp plates used for cell growth and experimental procedures require 
validation for fitness-for-purpose. Dr. Fermini, during his presentation at the 2015 SPS meeting 
(section 2.1), mentioned that the IC50 of cisapride varied from 28 to 62 nM when determined in two 
different types of plates, despite the application of the same assay protocol by the same technician. 
Hence, each key component of the automated patch clamp platform requires careful evaluation for 
data reproducibility and reliability. 
3.1.7 Solubility	of	test	articles	for	automated	patch	clamp	
Solubility of test articles may pose problems specific to HTS patch clamp platforms. Indeed, 
current HTS plates are generally passive microfluidic (low volume, small size) systems (Wikipedia, 
2016) that are characterized by high shear stress affecting the conformation of patched cells and 
delaying homogenous solubility of the tested compounds within the experimental well solution 
(Cioffi, Moretti, Manbachi, Chung, Khademhosseini, & Dubini, 2010; Kraly, Holcomb, Guan, & 
Henry, 2009). The latter issue is routinely addressed by formulating poorly soluble compounds with 
substances [e.g., dimethyl sulfoxide (DMSO)] that render test articles more readily bioavailable to 
the patched cells. However, to be successful this strategy should be accompanied by means to rapidly 
achieve the homogenous mixing of small quantities of drugs or solvent containing solutions (see 
section 3.3.5). Finally, to ensure that homogenous mixing is achieved, the platform should allow 
sampling of well solutions for the determination of test substance concentration to correctly assess 
the potency of the candidate drug under evaluation. 
3.1.8 Data	management	
Patch clamp dataset analysis should be standardized in terms of models used for IC50 (ICx and Hill 
coefficient of the concentration-response curve) calculations, minimal number of assays/data points 
to obtain meaningful, robust data, and correction methods for possible rundown phenomena. 
3.1.9 Expectations	from	ion	channel	patch	clamp	generated	data	
Ion channel patch clamp datasets generated by the ICWG-organized pilot studies with a set of 12 
reference drugs will be relayed to the ISWG to train the O’Hara-Rudy model (O'Hara, et al., 2011) to 
identify key parameters (metrics) that have the ability to cause modifications in the computationally 
derived AP signaling proarrhythmic potential. From these liability fingerprints, the computational 
model, once appropriately trained and calibrated for fitness-for-purpose, will be able toautomatically 
attribute a low/no, intermediate, or high proarrhythmic risk label to any candidate drug.  
 In silico assay 3.2.
Potential issues and solutions pertaining to CiPA in silico assay were discussed by Dr. Sara Dutta 
(section 2.3). In addition to these, the ISWG should consider developing simulations to assess the 
potential proarrhythmic danger of candidate drugs which block the IKs channel (Towart, Linders, 
Hermans, Rohrbacher, Van Der Linde, Ercken, et al., 2009), given the role of this channel in the 
cardiac repolarization process particularly during cardiac activation (Liu, Du, & Li, 2012). 
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 hiPSC-CM assay 3.3.
The objective of the CiPA hiPSC-CM assay is not only to verify the proarrhythmic predictions 
obtained from the in silico simulations but also to discover proarrhythmic mechanism(s) that the ion 
channel and in silico assays did not, or were not powered (e.g., disruption of cardiac channel 
expression and trafficking) to discover. 
3.3.1 Qualification of hiPSC-CMs for CiPA purpose 
Commercially available hiPSC-CM cell lines exhibit different mechanical, electrophysiological, and 
pharmacological properties (Ji, Kang, & Rampe, 2014; Millard, Chvatal, & Ross, 2015). Hence, in 
order to be adopted for the CiPA assay, they need to be carefully characterized for fitness-for-purpose, 
i.e. for their ability to generate the sought knowledge in a reproducible manner within and across 
laboratories. Issues deserving targeted attention are: 
1) Definition of requisite features of hiPSC-CM cell lines to be adopted for the CiPA paradigm; 
2) CiPA-specific procedures concerning cell seeding and growth in HTS plate wells; 
3) Desirable properties of cardiac ion channel expressed by hiPSC-CMs for the CiPA studies; 
4) Drug testing solution preparation;  
5) Homogeneous mixing of µL quantities of solutions containing testing agents within the 
experimental well and precautions to ensure that drug candidates are not adsorbed to platform 
wares; 
6) Adoption, if necessary for experimental purposes, of experimental platforms offering pacing 
capability; 
7) Study design; 
8) Data point sampling timing; 
9) Dataset analysis approaches. 
3.3.2  hiPSC-CM cell line features  
The phenotypic structure of current CMs is structurally and functionally characteristic of the 
embryonic and/or fetal development stage as documented by electrophysiological, calcium handling, 
and metabolic signatures exhibited by these cell preparations. Indeed, in contrast to native adult CMs, 
hiPSC-CMs have small cellular size, lack T-tubule structures and well-formed sarcomeres, and 
possess multiple nuclei, poor overall calcium storage and handling capability, and relatively small 
populations of mitochondria. In addition, their metabolic processes depend entirely upon glycolytic 
activity, and have intrinsic contractile automaticity (Ivashchenko, Pipes, Lozinskaya, Lin, Xiaoping, 
Needle, et al., 2013; Keung, Boheler, & Li, 2014; Robertson, Tran, & George, 2013; Roden & Hong, 
2013). The lack of working load for hiPSC-CMs in culture conditions is responsible for the absence of 
the development of a cellular sarcomeric organization during the maturation process which, in turn, 
results in a poorly organized syncytium lacking adult phenotypic characteristics. 
 18/41 
Intensive research efforts are ongoing for obtaining hiPSC-CMs exhibiting adult phenotypic 
features. Currently, any small progress toward the latter goal is obtained by hiPSC-CM production 
process changes which, in certain cases, are accompanied by changes in the pharmacological 
properties of hiPSC-. If the latter occurs, it infringes a central tenet of safety disciplines which 
stipulates that the biological material used for a safety test, particularly whenever performed for 
regulatory purposes, should, over time, provide reliable and reproducible datasets within and across 
laboratories. In order to fulfil this requirement, the production process of any hiPSC-CM line, if 
adopted for CiPA safety investigations, should be constrained to preserve the properties exhibited 
during the qualification process. To this end, it is incumbent on the manufacturers of hiPSC-CMs to 
ensure the consistency of cell products from batch to batch within the requirements of a Quality 
Management System (QMS) certified according to the International Organization for Standardization 
(ISO) principles. This entails, inter alia, that for experimental replication purposes, the manufacturer 
complies with ISO standards and maintains in its archive system (and, if requested, provides) 
documentation concerning the entire manufacturing process of any hiPSC- CM batch (World Health 
Organization, 2011). As a corollary to these basic principles, on material delivery the manufacturer 
has to inform investigators of any change in the production process of the hiPSC-CMs since this may 
require additional pharmacological validation assaysto assess whether the modified biological material 
responds to reference drugs in the same manner as established during the CiPA validation exercise. 
3.3.3 Cell seeding and growth into HTP plate wells 
The growth of hiPSC-CMs seeded into experimental wells uses solutions generally supplied by cell 
manufacturers. For proprietary reasons, the composition of these solutions is not always detailed on 
the container labels. It is, however, a safety assay requirement that the composition of any solutions 
used during the experimental procedure [for biological material preparation (monolayer 
differentiation) or assay execution] should be part of the experimental protocol. For example, if such 
culture or assay solutions contain proteins of animal or human origin (serum), they may modify 
candidate drug availability to the biophase sites. 
Whenever possible, the use of protein-free differentiation and recording media should be considered, 
particularly if these media work well for the selected hiPSC-CM line. For example, commercial media 
such as mTeSR (Stemcell™ Technologies, 2016) and Essential 8TM (Thermofisher Scientific, 2016), 
are claimed to increase reproducibility of hiPSC-CM culture and differentiation by eliminating the use 
of serum, serum replacements, or conditioned media. Relative to recombinant growth factors, 
chemically synthesized small molecules incorporated into protein-free media reduce variability and 
cost and enhance the robustness of the hiPSC-CM assays. Additionally, these substrates stabilize 
certain properties of the cell culture systems and improve hiPSC-CM maturation processes when 
complemented with soluble cues of 3D design (e.g. substrate physical form optimizing cell-to-cell 
contacts) that may facilitate hiPSC- CM electrophysiological maturation (Denning, Borgdorff, 
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Crutchley, Firth, George, Kalra, et al., 2015; Patel, Celiz, Rajamohan, Anderson, Langer, Davies, et 
al., 2015). 
Several hiPSC-CM manufacturers (e.g., Axiogenesis™, Pluriomics™) have developed proprietary 
protein-free media for their cell lines. End-users have also adopted personalized recipes for protein-
free media used in their experimental procedures [e.g., for CDI hiPSC-CMs (Harris, 2015). As such, 
the CiPA MWG should consider recommending the use of protein-free media for CiPA hiPSC-CM 
assays if the use of these solutions provides datasets of enhanced value compared to traditional, 
protein-containing media. 
3.3.4 Measuring platforms 
Platforms currently available for HTP determination of the electrical activity of hiPSC-CMs use 
MEA or VSD technologies (Cavero & Holzgrefe, 2015). 
MEA is a multi-well plate technology for label-free, real-time electrophysiological characterization 
of cardiomyocyte drug responses by recording extracellular field potentials (FP) from cell monolayers 
or clusters. Each well bottom is fitted with multiple recording electrodes [e.g., Maestro MEA system 
has a 16 electrode grid (Axion Biosystems, 2016b)]. 
MEA technology can be used to determine effects (concentration-response curves, time-course over 
a prolonged period) of test articles on FP. Endpoints from FP recordings include amplitude (FPA in 
µV), duration (FPD in ms), beat period (BP in s) from which BR (contractions per min = 60/BP] can 
be calculated. Arrhythmic events are quantified by the number of experimental preparations showing 
rhythm irregularities. Classifications of these irregularities have been proposed according to specific 
parameters (Gilchrist, Lewis, Gay, Sellgren, & Grego, 2015). 
Due to the variability of the FP shape, a critical issue concerns the selection of the control FP 
wave(s) to enable clear measurements of FP parameters (in particular FPD). The changes produced by 
a candidate drug on the baseline FP are used to determine proarrhythmic safety or liability of a 
candidate drug. To this end, four approaches appear applicable: 
1) Golden electrode. The underlying rationale is that monolayers of hiPSC-CMs are typically linked 
in an electrically coupled syncytium beating as a whole unit. As a result, the characteristics of the 
culture recorded at a given electrode could be considered to represent the activity detectable by 
any other electrodes within the well. Therefore, data points from a single electrode (i.e., the 
‘golden electrode’) exhibiting an excellent FP wave may be presumed to be representative of the 
entire preparation. A requirement for this approach is that the same electrode should be used for 
sampling baseline and drug or vehicle exposure data [Fig. 7 in (Clements, 2016)]. 
2) Well-wide mean. This refers to the mean response across all well electrodes. The morphology of 
the FP waves from the entire set of MEA electrodes is generally rather heterogeneous. In 
particular, some electrodes can display prominent repolarization waves and others none at all. 
This can result in the misidentification of a weak repolarization wave, in particular, by automatic 
detection software with possible inaccuracy in FPD measurements [Fig. 7 in (Clements, 2016)]. 
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The Cardiac Data Aggregation Tool within the AxIS software (Axion Biosystems, 2016a) allows 
setting user-specific boundaries for improving the accuracy of well-wide statistics. 
3) Golden FP wave. This is defined by the following criteria: FPA ≥200 µV, FPDcF ≥340 ms, and a 
second wave following the FP spike of ≥ 15 µV amplitude. This approach is used by Japanese 
investigators, as described in section 2.4. A requirement for this approach, as noted for the 
Golden electrode, is that the same electrode should be used for sampling data under baseline and 
drug or vehicle exposure conditions. 
4) Golden class. This method is proposed by NOTOCORD Systems through their NOTOCORD- 
Field Potential Screener (fps) (Notocord Systems, 2016). For each electrode, it clusters, FP 
waveforms recorded from all electrodes within a well according to morphology to ensure 
coherent measurements made over short sampling periods throughout the whole experimental 
time. Waveforms within each cluster (or class) are then averaged to improve the signal/noise 
ratio. The user has the possibility to select his quality control criteria for the first analysis period 
(used then throughout the experiment) for BR, acceptable maximal variability, cluster number, 
and beat number. These criteria allow the automatic selection of all electrodes that can be 
analyzed. Then, on each analyzable electrode, the software uses the most populated clusters for 
the calculation of the desired biomarkers (e.g., FPA, FPD, BP) 
The variability in the FP shape of the preparation generally recorded from the electrodes within the 
experimental well may have multiple origins, some of which are preparation specific (e.g., position of 
the electrode within the well in relation to the pacemaker driving the preparation, ground position, cell 
organization within the sheet, and differences in resistance and capacitance between myocytes and 
electrodes). 
The most relevant issues with MEA technology requiring appropriate resolution include: 
1) Determination of the time necessary to achieve homogenous mixing of the test article solution 
with the drug-free solution within the well. This may be a function of the solubilizing medium 
(e.g., use or not of DMSO) and amounts of drug-containing solution selected to replace the drug-
free solution; 
2) Validation of electronic amplifier circuits and all connected hardware (e.g. electrode forms and 
position in relation to grounds) necessary to measure FP waveforms; 
3) Use of a low frequency (0.1 Hz) digital filter for FP measurements in order to avoid information 
loss on recorded FP waveforms (Asakura, Hayashi, Ojima, Taniguchi, Miyamoto, Nakamori, et 
al., 2015); 
4) Identification of recording electrodes within the well for capturing FP waves clearly exhibiting 
the parameters to be measured; 
5)  Selection of the most pertinent FP endpoint parameters for further analysis; 
6) Detection and analysis of certain proarrhythmic events (EADs, beat-to-beat variability). 
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Voltage-sensitive dyes (VSD) and genetically-encoded voltage indicators [GEV (Q-State 
Biosciences, 2016)], together referred to as voltage sensitive optical probes (VSOs) can be used to 
measure the integrated AP generated by multicellular hiPSC-CM monolayers (Zhang, Gintant, & 
Pierson, 2014). Parameters that are generally calculated from these AP are BR, depolarization Vmax, 
APD30, APD50, APD90, AP triangulation (APD90-APD30) and number of proarrhythmic events such as 
early after depolarizations (EADs). AP shapes recorded with VSDs and the associated AP metric 
values (e.g., ADP90) may be specific to each hiPSC-CM line. 
3.3.5 There are several theoretical limitations to VSD and GEVI technology which have been succinctly 
summarized by Leyton-Mange and colleagues (Leyton-Mange et al., 2014): 1) Fluorescence signals 
report relative, not absolute, membrane potentials; 2) The slow temporal response of these VSOs 
results in loss of high frequency elements and leads to small but systematic overestimation of APD, 
although, VSD ANEPPS dyes have a faster temporal response to GEVIs (e.g. ArcLight). However, 
for the moment, this slow temporal response is not a critical issue since currently available hiPSC-
CM preparations exhibit low Vmax values than primary CMs (Robertson et al., 2013); 3) 
Phototoxicity associated with VSOs can limit the duration of experimental recordings. 
Comparatively, GEVIs have been reported to have a lower phototoxicity than VSDs (ArcLight vs. di-
4-ANEPPS and di-8-ANEPPS); 4) Additionally, a possible interaction of VSOs with the candidate 
drug should also be taken into consideration when using these technologies (Hardy et al., 
2009).Experimental platform offering the possibility of pacing the preparations 
Platforms offering the possibility of pacing hiPSC-CM sheets [e.g., (Axion Biosystems, 2016b; 
Multichannel Systems, 2016)] should be selected to determine the electrophysiological effects of 
drugs blocking IKs. Indeed, the activation of this channel occurs at high driving rates (Braam, 
Tertoolen, Casini, Matsa, Lu, Teisman, et al., 2013; Liu, et al., 2012). As such, the determination of 
the effects of a candidate drug at low and high pacing rates can provide key information on the 
potential proarrhythmic liability of a candidate drug. It should be noted that for spontaneously beating 
hiPSC-CM sheets, low pacing refers to a threshold rate just above the baseline rate (e.g., for CDI-iCell 
hiPSC-CM spontaneously contracting at ~60-times/min, stimuli delivered each 900-800 ms will raise 
the rate by 10-20 contractions). The baseline heart rate of hiPSC-CM sheets depends not only on the 
individual cell line under study but also on experimental protocol provisions (e.g., presence or not of 
glucose in the recording well solution). 
The 48-well MEA optical stimulation system Lumos® is claimed to provide artifact-free pacing 
(Axion Biosystems, 2016c). In this regard, it should be mentioned that other optical electrophysiology 
platforms for driving and recording the activity of hiPSC-CMs are now available and are based on 
proprietary ultrasensitive optogenetic reporters and actuators that convert APs into visible 
fluorescence flashes easily detectable by microscopy. These methodologies can also be used to deliver 
excitatory photo impulses to drive the preparation at a desired frequency (Q-State Biosciences, 2016). 
3.3.6 Properties of cardiac ion channels expressed by hiPSC-CM in growth wells 
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The populations of cells constituting hiPSC-CM sheets are likely to be heterogeneous in nature 
(Herron, et al., 2012) as the channel properties of each cell type depends on the progression from the 
initial embryonic to the successive fetal and final adult status. For example, the maximum diastolic 
potential (MDP) of commercially available hiPSC-CMs is relatively low or depolarized [e.g., more  
than -75 mV (Ma, Guo, Fiene, Anson, Thomson, Kamp, et al., 2011; Peng, Lacerda, Kirsch, Brown, & 
Bruening-Wright, 2010)]. This accounts for the sustained conducting (open) state exhibited by Na+ 
channels in commercially available hiPSC-CMs, in contrast to the closed or inactivated state displayed 
by these channels in healthy native resting CMs. These electrophysiological properties, characteristic 
of immature hiPSC-CMs, remain virtually unchanged even after maintaining CMs in established 
culture systems for prolonged periods. It is possible that the composition of culture media favors the 
persistence of the immature phenotype observed in currently available hiPSC-CM lines [Fig. 1 in 
(Drawnel, Boccardo, Prummer, Delobel, Graff, Weber, et al., 2014)]. Additionally, the structure of ion 
channels and the functional role of associated regulatory sub-units in hiPSC-CM lines remain to be 
determined. In order to shed light on ion channel expression issues, the new CRISPR Genome Editing 
technology could be used since it offers tools for easy site-specific DNA deletions, insertions, 
inversions, and replacements. These genomic manipulations would help researchers to understand the 
gene function in various cellular contexts, to explore the mode of gene regulation at endogenous loci, 
and, most importantly, to model human disease conditions in in vitro cellular and in vivo systems 
(Shui, Hernandez Matias, Guo, & Peng, 2016) since patients harboring genetic disease are the most 
vulnerable human subjects to drug-induced proarrhythmic events. 
A further issue with spontaneously beating hiPSC-CM sheets is whether either multiple 
synchronized or master pacemakers are responsible for the innate automaticity of pulsating monolayer 
syncytia. This information would be extremely useful for improving the analysis of FP waveforms, the 
shape of which varies with the contractile state of the preparation. A potential solution for this issue 
could be the adoption of standardized pacing protocols for hiPSC-CM assays. Alternatively, 
preparations exhibiting continuously changing sites of contraction initiation could be excluded from 
analysis. The acquisition software that accompanies the Maestro 48-/96-well MEA system allows the 
identification of the well site where the contractile wave starts (Axion Biosystems, 2016a). 
The relative contribution of individual ion channels to FP shaping is poorly understood. The current 
knowledge on this matter is primarily provided by pharmacological maneuvers using channel blockers 
which are presumed to bind selectively and specifically to the channel under investigation (Ma, et al., 
2011). However, the relative specificity and selectivity of these agents are properties which have not 
been established in hiPSC-CM preparations, but rather in conventional in vitro/in vivo preparations 
fully expressing functional and structurally organized human and non-human ion channels that have 
been studied under well-defined experimental conditions. Hence, the selectivity and efficacy of 
reference pharmacological agents remain to be established in immature hiPSC-CMs. 
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It should also be noted that no information is available on whether epi-, mid-, and /or endo-
myocardial cells are present and, if so, which role(s) they play, in hiPSC-CM monolayer syncytia. 
Since these cell types mediate repolarization dispersion, this crucial mechanism responsible for 
triggering arrhythmia in the integrated human heart (Burton & Cobbe, 2001) cannot be currently 
evaluated in hiPSC-CM monolayer preparations. 
Finally, the genetic background of available hiPSC-CM lines is generally not provided by the cell 
suppliers. Yet, this information could offer critical insights on CM line-specific characteristics. 
3.3.7 Diffusion and time necessary for homogeneous mixing of candidate drug solutions within the 
experimental well 
When the effects of candidate drugs on the electrical activity of hiPSC-CM are determined in 
48/384 well platforms (e.g., study volume in each well of a 48 well plate is 450 µL per well), specific 
attention should be given to several potential issues. 
Tight and homogeneous adherence of hiPSC-CM monolayers to the well floor should be ensured to 
obtain reliable FP measurements. Although this issue is now of reduced concern if fibronectin- or 
Kapton-coated wells are used, deficient adherence can cause trapping of part of the bath solution 
between the non-adhering cells and the well bottom. This phenomenon can prevent or delay mixing of 
the trapped solution with the drug-containing solution or expose non-adherent cell surfaces to the 
candidate drug. The non-adherence can be verified by using, for example, light green SF yellowish 
dye. When a drop of this dye is added to the well solution, the colored fluid surrounds the adherent 
cell monolayer but, in the presence of non-adherence, it rapidly penetrates between non-adherent cells 
and the well floor. The time to obtain a homogenous mixing of this dye with the well solution (300 
µL) was found to be 10-15 min. This observation demonstrates that for small volume wells, the time 
for obtaining homogenous mixing between drug-free and drug-containing solutions (the density of 
which may differ from that of the control medium) should be experimentally assessed. The latter 
remark highlights a possible issue that may derive from the amount of a DMSO-solubilized drug that 
is selected for replacing the drug-free well solution. For example, if the desired final concentration of a 
drug solubilized in 0.3% DMSO within a 300 µL well is 300 pM (300 pM/mL) and this has to be 
achieved by replacing 1/30 of the total well solution (i.e., 10 µL), then the added 10 µL solution 
should contain 9000 pM of the candidate drug.  
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However, to achieve the same final concentration (300 pM) by replacing 1/2 (i.e. 150 µL) of the 
total well drug-free solution, the added 150 µL of a drug stock solution should contain 600 pM of the 
candidate drug. The 10 µL solution of 9000 pM of drug in 0.3% DMSO has a higher density than the 
150 µL solution of 600 pM. Under the static microfluidic mixing conditions of currently used multi-
well plates (Cioffi, et al., 2010; Kraly, et al., 2009), the small quantity of solution with the higher drug 
concentration reaches the cell monolayer attached to the floor of the well before becoming uniformly 
mixed with the drug-free solution. This may explain the results depicted in Fig.2 which were obtained 
in experiments conducted at 37°C by replacing 1/2 and 1/30 of the drug-free well medium with 
matched volumes of drug solubilized in an appropriate quantity of DMSO to achieve the same final 
well drug concentration 
containing 0.3% DMSO (v/v). 
Fig. 2 reports FP tracings 
recorded from 2 sets of 2 
contiguous wells located in the 
same experimental plate 
containing cell sheets grown 
from the same hiPSC-CM 
batch and subjected to the 
same experimental procedure. 
Although the preparations 
were theoretically exposed to 
the same final concentration 
(300 pM) of a proprietary 
hERG blocker by replacing 
1/30 and 1/2 of the well drug-
free solution, the observed 
effects were dramatically different. Indeed, almost full inhibition of the FP (persisting for the 30-min 
of the experimental procedure) was produced by the addition of 10 µL of a 9000 pM drug solution, 
while no effect was produced by 150 µL of a 0.6 nM drug solution. DMSO (0.3%) used to solubilize 
the drug cannot be considered responsible for the effects produced by the 10 µL solution containing 
the candidate drug since the matched 10 µL control solution containing only DMSO did not affect FP 
responses. 
This problem could be avoided if the platform allowed the continuous superfusion of the 
preparation with solutions containing the desired final concentration of the drug. However, this would 
increase background noise and require greater system complexity and far larger amounts of test article. 
In view of these observations, it would appear that the largest possible volume not affecting the 
contractile activity of the preparation should be replaced to achieve the desired final concentration. 
 
Fig 2. Effects of final drug concentration (300 pM) in 300 µL well 
achieved by replacing 150 µL (well A-1 and A-2) or 10 µL (B-1 and B-
2) drug-containing solutions on the FP in hiPSC-CMs. Control 
responses were obtained by adding the same volumes of solution for 
achieving a 0.3% DMSO content in the final bath volume. 
Substitution	of	1/30	of	drug-free	volume	(300	µL)		of	the		
well	by	10	µL	of	a	solution	containing	9000	pM of	drug	X
Well	B-2Well	B-1
Well	A-1 Well	A-2
90	s	after drug X	 90	s	after drug X	
90	s	after drug X	 90	s	after drug X	
10	s 10	s10	s 10	s
Substitution	of	50%	of	drug-free	volume		(300	µL)	of	the	well
by	150	µL	of	a	solution	containing	600	pM of	drug	X
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Additionally, if the responses to small volume containing high test article concentrations appear 
exaggerated, the possible influence of the density of the added solution in the observed response 
should questioned and verified by appropriately designed experimental procedures that avoid the use 
of very small quantities of drug-containing solutions which are generally used for the construction of 
concentration-response relationships in small volume wells. 
3.3.8 Study design 
The study protocol for the CiPA hiPSC-CM assay should incorporate the knowledge provided by the 
in silico assay. Since the final effects of the candidate drugs may change with length of the exposure 
time, time point measurements for short duration assays should be carefully standardized to allow 
comparisons across assays and laboratories. If warranted by the candidate drug therapeutic mechanism 
(e.g., biopharmaceutical anticancer agents), the effects of the candidate drug on ion channel expression 
and trafficking mechanisms should be assessed, if possible, during a prolonged (>8h) exposure of 
hiPSC-CMs to the test article (Guo, Coyle, Abrams, Kemper, Chiao, & Kolaja, 2013; Himmel, 2013). 
For this type of assay (but ideally also for short duration assays), recording and maintenance media 
should be identical in nature, notably in terms of protein content to avoid potential undesirable drug 
binding and pH effects, which can affect drug solubility and receptor availability. 
3.3.9 Sampling frequency and timing 
Data sampling times and frequency should be selected to provide the best evidence possible in favor 
of, or against, proarrhythmic liability of a candidate drug. In particular, it is crucial to generate data at 
steady-state conditions, as this is a fundamental pharmacological tenet for calculating IC50 values 
correctly. However, if arrhythmic events (EADs) occur at steady state, FPD measurements should be 
performed before their manifestation, or disregarded, since arrhythmia is a more meaningful 
proarrhythmic signal than FPD prolongation. Whereas EADs occurrence is a major indicator of a 
proarrhythmic potential of a candidate drug, the absence of EADs cannot be taken as an indication of 
the absence of proarrhythmic risk. The analysis of FP and AP datasets can make use of conventional 
or data-tailored methods, as discussed below. 
3.3.9.1 Conventional dataset analysis 
FP (FPA, FPD, BP or BR) and AP (ADP50, ADP90) parameters from a meaningful number of 
preparations are conventionally reported as means plus/minus associated errors [(Standard deviation 
(SD) or standard error of the mean (SEM)]. Additionally, if concentration-response datasets are 
available, the concentration inhibiting the response by 50% (IC50) should be calculated together with 
associated parameters such as the slope and the maximum of the concentration-response curve. The 
logistic model to be used for such calculations should be recommended by a CiPA expert team in 
order to minimize possible data analysis variability due to use of different models and fitting options 
(e.g. methods to weight data for optimized fitting). 
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The experimental protocol should clearly define the FP or AP parameters to be selected to support 
proarrhythmic liability conclusions for the candidate drug and the threshold changes (e.g., FDP 
increase >20%) or X number of EADs within a given time period) for assuming that the observed 
effects are of biological significance. 
3.3.9.2 Application of QT correction algorithm to FPD 
An issue requiring a specific comment concerns the standardization of the FPD to a reference-
beating rate to remove the possible influence of heart rate differences across preparations and hiPSC-
CM lines. Many CiPA investigators standardize FPD values as if it were an ECG QT interval by 
considering that its duration is inversely related to the contracting rate of the preparation. Indeed, ECG 
QT intervals are generally corrected according to Bazett or Fridericia formulas (QTc) to obtain values 
for a reference heart rate of 60 beats/min for  inter-subject (or inter preparation) comparisons (Davey, 
2002). Several investigators apply this method to FPD analysis (Asakura,et al., 2015; Harris, Aylott, 
Cui, Louttit, Mcmahon, & Sridhar, 2013; Nakamura, et al., 2014; Navarrete, Liang, Lan, Sanchez-
Freire, Simmons, Gong, et al., 2013). However, they do not provide experimental evidence to justify 
the application of either the Bazett or Fridericia algorithm to FPD values generated in 
electrophysiological assays with  hiPSC-CMs (Cavero & Holzgrefe, 2015). For the moment, a less 
than optimal solution to this issue could be the reporting of uncorrected and corrected FPD values 
(Clements, Millar, Williams, & Kalinka, 2015; Clements & Thomas, 2014) to enable comparison with 
publications which exclusively report corrected FPD data. Recently, electrical pacing has been used to 
demonstrate that the optimal FPD correction factor for CDI hiPSC-CMs is intermediate of Bazett's and 
Fridericia's formulae (Axion Biosystems, 2016b). 
3.3.9.3 In silico approaches to FP analysis 
Computational in silico models of cardiac electrophysiology are now available and routinely used for 
reconstructing the AP and determining the contribution of key ion channels to the AP formation 
(Corrias, Giles, & Rodriguez, 2011). However, although FP data acquired by MEA technologies have 
not yet received extensive attention for simulation purposes, such efforts are ongoing as indicated by 
posters presented at the 2014 (Zitoun, Raphel, Boulakia, & Gerbeau, 2015) and 2015 (Bowler, Harris, 
Gavaghan, & Mirams, 2016) Annual Meetings of the Safety Pharmacology Society. 
Examination of the relationships linking FP electrical signals to AP profiles is possible by using 
mathematical models incorporating partial differential equations (bidomain equations) for adequately 
describing the time- and space-dependence of intra- and extra-cellular electrical potential diffusion 
within the hiPSC-CM monolayers in experimental wells. By making the reasonable assumption that 
the FP is the electrical phenotypical manifestation of extra-cellular potentials, bidomain equations can 
convert FPs into APs and vice versa. This computational approach can be designed to integrate 
information concerning MEA well geometry and size, electrode surface areas, and positions within the 
well, etc. The model also needs to include values for the extra-cellular potential, or its derivatives, at 
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the boundary of the computational domain. These "boundary conditions" can be established, for 
example, on the observation that FP vanishes on that portion of the well connected to the ground wire, 
or that extracellular currents normally vanish on any insulated portion of the boundary. 
Bidomain equations are necessarily based on an appropriate cell model. This in silico approach 
should be viewed, therefore, as an extension of, rather than an alternative to, the in silico model used 
to describe APs on their own. In other words, the FP model can provide reliable information only if it 
is based on a reliable cell models. Recently, a computation model for the electrophysiology behavior 
of hiPSC-CM line has been published (Paci, Hyttinen, Aalto-Setala, & Severi, 2013), but the fact that 
various commercially available hiPSC-CM lines exhibit different mechanical, electrophysiological, 
and pharmacological properties, implies that FP models should be developed by taking into 
consideration the electrophysiological features of the hiPSC-CM line of interest. 
Bidomain equations used to model FPs recorded with MEA technology are constructed assuming a 
homogenization process which assumes that the system generating FPs is explored at a scale 
substantially larger than the scale of the cells generating these signals. However, rejecting the latter 
assumption would require resolving the spatial scale of each single cell of the biological preparation, 
an approach which dramatically increases the complexity of the computational approach. 
 
Fig. 3. Conversion of 4 in silico FPs [obtained by means of a computational model developed 
from electrophysiological data obtained in hiPSC-CMs (Paci, et al., 2013)] into AP profiles 
(Zitoun, et al., 2015). Note the qualitative agreement between simulated and experimentally 
obtained FPs in in vitro hiPSC-CMs assays. The in silico FPs, despite being obtained from 
homogenous cell sets, exhibit shape differences. The geometry used for this simulation 
corresponds to a 60-6 well MEA by Multi Channel Systems (Multichannel Systems, 2016). 
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In spite of the aforementioned issues, promising results have been recently obtained with the 
bidomain incorporating an electrode model (Zitoun, et al., 2015) based on the  model of hiPSC-CM.  
The in silico FPs obtained within this framework (Fig 3) appear to be in good qualitative agreement 
with the FPs recorded from in vitro experiments (Zitoun, et al., 2015). Additionally, such a model can 
be used to scrutinize various aspects of the FP which are difficult to clarify in wet assays. For 
example, inter-electrode variability in FP forms, routinely observed in biological assays and generally 
attributed to the phenotypic expression of the different cell types constituting the hiPSC-CM 
monolayer, is reproducible in computer simulations using monolayers of perfectly homogeneous cells. 
Interestingly, there are configurations where the differences in FP shapes, relayed by spatially 
separated electrodes, do not translate in notable AP shape differences. 
In silico models of FP can also be used to further our understanding of the effects of ion channel 
blocking drugs on the shapes of FPs obtained in hiPSC-CM experiments. 
The in silico analysis of the FP based on a cell model is referred to as a forward (or direct) problem 
analysis whereas the inverse problem refers to the determination of cell AP properties derived from 
biologically measured FPs. For example, the application of inverse problem solutions could be 
exploited to automatically identify the ion channel species affected by a drug from the experimental 
FP data and underlying cell model. However, the results of the in silico FP models cannot outperform 
the in silico AP model upon which they are based. Hence, if the effects of a channel blockade are 
difficult to interpret on the simulated AP, the simulated FP would be unable to provide additional 
information. Ongoing computational efforts are expected to generate additional tools for rendering FP 
measurements generated by MEA platforms as informative as possible, particularly in the 
determination of the effects of candidate drugs on ion channel functions. 
4. Discussion 
The first part of this report reviews presentations delivered at the ‘CiPA on my mind’ session held at 
the 2015 Annual Meeting of the Safety Pharmacological Society. The presentations commented on 
accomplished, ongoing, and future activities of selected CiPA working groups for the qualification of 
the CiPA paradigm. 
The second part of the report analyses a series of key issues requiring expedited solutions for the 
completion of initial testing and successive validation activities of CiPA core assays. Although it 
proposes possible solutions to certain issues it will be the role of CiPA Steering Committee and CiPA 
specialized working Groups to provide documented guidance on how these issues should be handled, 
particularly by bench investigators. In the absence of such an official intervention, substantial delays 
in the implementation of the CiPA as a valuable Safety Pharmacology strategy are likely to occur. 
 Considerations on the ‘CiPA on my mind’ session held at the 2015 Annual Meeting of SPS 4.1
The presentations on CiPA at the 2015 SPS Annual Meeting delivered limited new information in 
relation to the Dec 2014 CiPA Update Workshop (Cavero & Holzgrefe, 2015). 
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The Leaders of the Ion Channel Working Group (ICWG) informed the audience that the drafting of 
a physiological and dynamic block protocols for each of the seven cardiac ion channels selected as 
potential key investigational targets for the CiPA paradigm had been completed. Additionally, the 
testing of these protocols concerning the hERG channel had been successfully achieved in manual 
patch clamp platforms. However, the screening technology for CiPA ion channel assays will be the 
automated patch clamp platform [which lacks the experimental flexibility of the manual patch clamp 
approach (Danker & Moller, 2014)]. The adaptation of the ICWG hERG ion channel protocols to 
automated patch platforms remains to be done. If the protocols for the remaining six channels of 
interest have to be tested manually and then adapted to automated patch clamp platforms, an updated 
plan for expediting this process should be devised and implemented. 
The substantial resources spent so far by the ICWG for optimizing hERG channel protocols are 
justified by the recognized crucial role played by this channel in drug-induced lethal arrhythmia 
(Kannankeril, et al., 2010; Vandenberg, et al., 2012). Nevertheless, the protocol optimization process 
for automated patch clamp platforms concerning other cardiac ion channels should be accelerated. 
The ongoing and future activities for the CiPA in silico assay were detailed at the ‘CiPA on my 
mind’ session. In particular, Dr. Sara Dutta emphasized that the successful training of the O’Hara-
Rudy model with the set of twelve reference proarrhythmic drugs relies entirely on the quality and 
reliability of experimental data generated by the ICWG studies. It was also stressed that the input 
metrics should be quantitative in nature, drug mechanism-linked, and ultimately allow the 
classification of candidate drugs into one of three categories of risk (no/low, intermediate or high) as 
established by the CiPA Clinical Translation Group (Cavero & Holzgrefe, 2015). Metrics with these 
features will have to be obtained by using best practice protocols in optimized ion channel assays 
carried out desirably in automated patch clamp platforms. 
Special mention deserves the novel TdPrisk metric since it succeeded in correctly classifying each of 
12 established proarrhythmic drugs (Fig. 1) although it should be noted that the generation of the data 
necessary to calculate it may not be easily accomplished in automated patch platforms and will be 
expensive, particularly if this has to be done in manual patch clamp studies as was the case for the data 
presented in Fig. 1 (Crumb, et al., 2016). However, if such a novel metric provides robust and reliable 
information on the intrinsic proarrhythmic risk of a very promising drug candidate, it may be sought 
whenever a questionable safety signal is suggested by the overall CiPA studies. It is also important to 
keep in mind that the data presented in Fig. 1 are not the only possible ones for the correct 
classification of the 12 drug data set since various avenues are still being investigated, including a 
dynamic hERG model and an improved representation of INaLate. 
Drs. Sekino and Sugiyama (sections 2.4 and 2.5) discussed the contribution of Japanese 
organizations to the international CiPA validation efforts, including a 60 drug study to be performed in 
2016. The primary goal of this study, in order to adopt appropriate correction measures, is the 
discovery of potential causes for the high inter- and among-laboratory variability currently 
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characterizing CiPA hiPSC-CM assays. To this end, the adopted protocol stipulates the application of 
strictly standardized conditions for which the technical teams of four geographically separated 
laboratories received specific training. However, certain protocol provisions may merit reconsideration 
in the light of issues detailed in section 3.2 of this report which deals with various potential concerns 
around biological material, experimental platforms, cell growth and testing solutions, small volumes 
of drug solutions added to the experimental well for generating concentration-response curves, and 
data analysis still requiring optimization. Additionally, the JiCSA consortium study protocol, despite 
the remarkable efforts to pinpoint causes to be corrected to constrain bench-related data variability 
(Kitaguchi, Moriyama, Taniguchi, Ojima, Ando, Uda, et al., 2016), may not have given sufficient 
weight to concurrent causes which are independent of the experimental laboratory setup. These 
include, for example, the manufacturing processes of the hiPSC-CM batches, and seeding, growing, 
and testing solutions. Indeed, if these experimental solutions contain animal or human sera, even strict 
control of the manufacturing procedure of these materials may not be sufficient to prevent possible 
between-manufacturer differences in the amounts of proteins (in particular growth factors) that can 
cause changes in the pharmacological properties of each newly produced batch of material. If this 
were the case, part of the knowledge provided by the Japanese efforts to standardize the CiPA hiPSC-
CM assay would not be entirely translatable to novel batches of biological material or solutions 
required for seeding and growing cells or testing drugs. Hence, such commendable standardization 
activity  to reduce dataset variability may risk introducing systematic errors in the experimental 
protocol assumed to be optimized. y. Therefore, it is essential that any standardization procedures for 
in vitro CiPA assays adopt experimental conditions that take into account, and attempt to correct, any 
possible intra and extra laboratory sources of experimental data variability. For example, the use of 
seeding, growing, and testing solutions used for CiPA hiPSC-CM assay containing uncharacterized 
factors (e.g., human or animal sera) should be circumvented, whenever possible, and replaced by well-
defined, currently available, chemically homogeneous media (Denning, et al., 2015; Patel, et al., 
2015). Indeed, the ongoing rapid improvements of experimental tools could quickly render obsolete 
prior systematic validation of the CiPA hiPSC-CM assay. 
 Considerations for core CiPA assay components needing targeted attention 4.2
Cardiac toxicity represents a leading cause of drug attrition along the nonclinical and clinical drug 
development paths (Ferri, Siegl, Corsini, Herrmann, Lerman, & Benghozi, 2013). Extensive ongoing 
international efforts are directed at validating the CiPA paradigm as a nonclinical drug safety strategy 
for the identification of candidate drugs with proarrhythmic potential. However, any strategy 
engineered to attain this objective is contingent, inter alia, on rigorous characterization of each crucial 
component of the experimental model. The core of this report highlights various pending issues for the 
in vitro CiPA assays that will require focused attention by the CiPA Steering Committee, CiPA 
Working Groups, and bench investigators striving to achieve the qualification of the CiPA paradigm. 
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4.2.1. In vitro ion channel assay 
The mission of the ICWG can be considered successful only when it delivers optimized and 
validated automated patch clamp platform protocols providing, for each key cardiac current, easily 
generated metrics that, when fed into the in silico model (O'Hara, et al., 2011), can predict with 
confidence the degree of proarrhythmic danger of a candidate drug. 
It is noteworthy that the adaptation of optimized manual patch protocols for INaLate, ICaL and IKs to 
automated patch clamp platforms may pose specific problems if HTP patch clamp protocols have to be 
of simple execution, reasonably priced, and, at the same time, generate robust and reliable 
proarrhythmic metrics.  
4.2.2. In vitro hiPSC-CM assay 
The optimization of the hiPSC-CM assay appears to be particularly challenging due to thepending 
issues concerning biological material, and numerous assay variables that need to be locked down. 
As emphasized earlier, all commercially available hiPSC-CM lines have not yet been scrupulously 
characterized as far as structural, electrophysiological, and pharmacological properties are concerned 
in relation to native human adult left ventricular CMs. These potential hurdles could be circumvented 
by clearly defining the advantages and limitations of any cell line selected for the CiPA hiPSC-CM 
assay and by interpreting the results obtained in this assay in the light of published evidence 
concerning ‘abnormal’ responses produced by certain drug classes in this biological material (Jonsson, 
Vos, Mirams, Duker, Sartipy, De Boer, et al., 2012; Kang, Chen, Ji, Lei, & Rampe, 2012). If 
warranted by the experimental results, the need of complementary assays to address unclear results 
should be considered and implemented.  
A further issue with hiPSC-CMs concerns the selection of cell lines that are guaranteed by the 
producer to preserve constant pharmacological properties from batch to batch. This requires that the 
production process be strictly controlled to prevent any drift in the hiPSC-CM maturation status 
(currently a major preoccupation of manufacturers) for the CiPA CM assays. However, the latter 
limitation may be overcome if the improved hiPSC-CM cell lines are subjected to a novel standardized 
pharmacological validation. The CiPA Myocyte Working Group (MWG) is about to propose the use 
of a set of positive and negative reference drugs as a validation procedure for improved cell line. 
In section 3.3, additional issues with the hiPSC-CMs were discussed. In particular, experimental 
evidence has been presented (Fig. 2) indicating that the volume of the drug-containing solutions used 
to replace the drug-free well solution can markedly affect experimental results. Indeed, while 10 µL of 
a DMSO solution containing a large concentration of a hERG blocking drug stopped FP generation, a 
volume of 150 µL giving the same final bath concentration of test article and DMSO had no effect. It 
should be emphasized that if small volumes containing large concentrations of a drug that binds 
irreversibly to key ion channel receptor sites are used to construct concentration-response curves in 
small volume wells, the drug dilution process will be unlikely to result in a rapid homogenous 
equilibrium between the bath solution drug levels and the drug receptor biophase. This is a 
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fundamental issue to be addressed for the construction of reliable and scientifically sound 
concentration-response curves. As illustrated in Fig. 2, failing to satisfy this requirement may result in 
classifying a drug substantially more potent than it is in reality. Another issue on test article evaluation 
concerns any drug candidate with reduced solubility in the testing solution. This also may lead to 
faulty estimations of drug potency.  
4.2.3. In silico analysis of FP data generated in the hiPSC-CM assay 
The analysis of experimental FP is often performed employing questionable criteria. For instance, 
certain investigators (Asakura, et al., 2015; Nakamura, et al., 2014) have overcome the differences in 
FP shapes measured from the various electrodes present within the experimental well by selecting 
‘good looking’ FP shapes (e.g., golden FP) satisfying pre-established criteria for the calculation of 
parameters (e.g., FPA, FPD) necessary for the determination of the proarrhythmic potential of 
candidate drugs. This does not appear to be a robust scientific approach. Similarly, the FPD is often 
taken to reflect the QT interval of the ECG and thus, on this assumption, standardized at a reference 
beating rate [e.g., 60 contractions per minute as done for human ECG) to remove the influences of 
variable beating rates across preparations and cell lines (Asakura, et al., 2015; Harris, et al., 2013; 
Nakamura, et al., 2014; Navarrete, et al., 2013)]. However, this approach should be justified by 
experimental data since the spontaneous contractile rate of hiPSC-CMs is not only determined by the 
pacemaker driving the preparation but also by the FPD (it is recalled that beating rate is inversely 
proportional to FPD: the higher is the rate and the shorter is FPD and vice versa). Algorithms used for 
the rate-correction of the QT-interval of the ECG are not powered to handle the contribution of the 
repolarisation phase to the beating rate. 
In silico simulations of FP can provide insights difficult to obtain in biological assays or traditional 
analytical approaches. For these purposes, the use of systems of differential equations necessary to 
model the time and spatial nature of FP signals provides a straightforward relationship between FP 
signals and AP profiles which can be readily used for the derivation of proarrhythmic-relevant 
parameters (e.g. APD50 and APD90, triangulation). Simulation experiments do not support assumptions 
based on visual observation concerning the variation of FP shapes recorded with MEA technology (see 
Fig. 3.). Indeed, they indicate that the variability of the FP shapes recorded from different electrodes 
within the experimental well are not necessarily the reflection of the activity of different cell types 
entering into the formation of the hiPSC-CM monolayer. It is more likely that FP shape variability is 
due to the position of the electrodes within the experimental well in relation to the pacemaker cells 
driving the monolayer contractions, or to ground electrodes. Indeed, simulation conditions using 
homogeneous cell features within the monolayer show that the shapes of FPs recorded from spatially 
separated electrodes are not identical (Fig. 3). This supports the usefulness of simulation studies to test 
hypotheses and to generate insights on certain in vitro observations whereupon hypothesis may be 
based. 
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The use of simulation studies to facilitate the solution of biological problems is an opportunity 
offered by the current availability of potent computational tools. In line with this tenet, the CiPA 
paradigm has also incorporated such an approach for predicting the proarrhythmic risk of candidate 
drugs from in vitro ion channel datasets. The introduction of in silico simulations using FP and AP 
data generated in hiPSC-CM studies could be a logical complement to the CiPA simulation assay. 
Indeed, such a novel tool could be used to predict proarrhythmic risks and the possible mechanisms 
mediating such risks. Additionally, the results of this analysis could be compared to information 
provided by the computational reconstruction of the AP by using channel assay generated metrics. 
Since the hiPSC-CMs are, for the moment, an integrated humanoid experimental material, 
computational analysis of results obtained from its experimental use may have a greater human 
translational power than those from the cloned ion channel assays. 
The above reflections might be considered too optimistic in view of the fact that the proposed in 
silico analysis of FP is based on a cell line-specific model of hiPSC-CMs (Paci, et al., 2013) and thus 
it may not be applicable to FP measures made from other cell lines. This judicious objection can be 
partly addressed by noting that any in silico model is built on data which do not incorporate the 
universal complexity of the biological system modelled. This is also the case for the O’Hara-Rudy 
model (O'Hara, et al., 2011) adopted for a core assay within the CiPA paradigm. Nevertheless, the 
proposed in silico simulations are likely to provide knowledge common to multiple hiPSC-CM cell 
lines. Moreover, future development of cell line-specific mathematical models (Bowler, et al., 
2016)will help to further refine these models (Johnstone, Chang, Bardenet, De Boer, Gavaghan, 
Pathmanathan, et al., 2015). 
 Good laboratory practices (GLP) for CiPA assays 4.3
An issue mentioned in a previous report (Cavero & Holzgrefe, 2015) concerns the requirement of 
GLP application to any CiPA assays. The established policy for safety studies carried out for 
regulatory purposes is that they should be run in the observance of GLP principles. Therefore, it is a 
decision of regulatory authorities to wave such a requirement if this cannot be scrupulously applied to 
a given assay. Nonetheless, if this were this case, the sponsor would, in our opinion, be expected to 
justify the non-application of GLP and provide the best possible documentation concerning the 
possibility to accurately replicate an assay provided to regulatory authorities in support of the 
proarrhythmic safety of a candidate drug. 
Since discussions are ongoing on the possible incorporation of all or part of the CiPA paradigm into 
the upcoming revision of the ICH S7B guideline, the issue of GLP for CiPA assays is likely to be 
matter of reflection at the level of the ICH organization. 
 Discrepancies between the in silico and the hiPSC-CM assays 4.4
If the results from the in silico model and the in vitro hiPSC-CM assay are in agreement, then a 
decision on successive development steps may be more straightforward. However, if the conclusions 
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derived from the two assays diverge, how can CiPA investigators clarify the discrepancy? This may be 
the case when the in silico (or the hiPSC-CM) assay results portend proarrhythmic liability but the 
hiPSC-CM assay (or the in silico assay) provide contradictory evidence. In this case, the application of 
the in vivo strategy recommended by the S7B (ICH, 2005a) could be invoked in an attempt to resolve 
the discrepancy. To this end, the CiPA Steering Committee should envisage complementing the 
current version of the CiPA in vitro and in silico strategy with a follow-up nonclinical in vivo assay as 
proposed by the S7B guideline (ICH, 2005a). Alternatively, data generated by using human primary 
cardiac tissues (Page et al., 2016) may be sought to provide a more relevant answer when the CiPA 
data package does not provide satisfactory proarrhythmic safety evidence concerning a therapeutically 
promising drug candidate. 
 General conclusions 4.5
Significant scientific advances often require the adoption of cutting-edge technologies, which 
initially do not operate at their intrinsic potential, but with time and hard work, are likely to fully 
satisfy envisaged expectations. This consideration applies to CiPA, an innovative Safety 
Pharmacology paradigm which is grounded on teachings from recent scientific advances and 
development of novel technologies. The approach adopted to enter CiPA into the Safety 
Pharmacology laboratory armamentarium diverges from the strategy followed by the ICH organization 
which previously recommended the blind adoption of harmonized strategies prepared by Expert 
Working groups (Cavero & Crumb, 2005). The latter consensus documents generally proposed the use 
of established experimental tools without subjecting them to a systematic validation for the envisaged 
purpose because they had been traditionally applied, but often not for specific Safety Pharmacology 
purposes. In this regard, the decision taken by the CiPA Steering Committee to qualify the CiPA 
safety tool prior to the official adoption should be considered revolutionary in nature. It should not be 
surprising that the path to achieve such a qualification goal has encountered and will encounter 
difficulties requiring solutions and reflection as they arise. This is also because the Safety 
Pharmacology community has no previous experience on how to accomplish a qualification process in 
a structured manner. If the establishment of CiPA, as a qualified Safety Pharmacology drug 
development strategy succeeds, it may become a reference to be followed by regulatory organizations, 
even for ICH guidelines calling for the use of traditional assays. It is recalled that the costs, supported 
by the pharmaceutical industry (and ultimately by patients), to optimize the S7B (ICH, 2005a) and 
E14 (ICH, 2005b) guideline assays have been unnecessarily excessive and required many years of 
trials and failures post official implementation to achieve the current status. As such, future ICH 
guidelines should be subjected to a formal validation process prior to their official adoption. The 
adoption of this proposal requires industrial and governmental support and resources as well as the 
nomination, within the ICH, of a Committee in charge of the qualification process for future 
experimental strategy proposed by any ICH Expert Working Group. Qualification is not a consensus 
between ICH partners concerning a strategy, but rather a process generating scientific evidence and 
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objective proofs that the proposed experimental approach is scientifically valid, robust and fit for the 
envisaged purpose.  
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